Gender | Age
Item
female patients, >=18 years of age;
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
HER2-positive carcinoma of breast
Item
her2-positive breast cancer;
boolean
C1960398 (UMLS CUI [1])
Metastatic cancer site Quantity Amenable Core biopsy
Item
al least one metastatic site amenable for core biopsy;
boolean
C0280457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C3900053 (UMLS CUI [1,3])
C1318309 (UMLS CUI [1,4])
Left ventricular ejection fraction
Item
left ventricular ejection fraction >50%.
boolean
C0428772 (UMLS CUI [1])
Herceptin Adjuvant | Herceptin Neoadjuvant
Item
prior adjuvant/neoadjuvant herceptin within past 6 months;
boolean
C0338204 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
C0338204 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
Taxane Adjuvant therapy
Item
prior adjuvant taxane therapy within past 12 months;
boolean
C0215136 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
Chemotherapy Malignant Neoplasms | Immunotherapy Malignant Neoplasms | Biological treatment Malignant Neoplasms
Item
use of chemotherapy, immunotherapy or biological anticancer therapy within past 3 weeks;
boolean
C0392920 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C1531518 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
Bleeding tendency
Item
known bleeding diatheses.
boolean
C1458140 (UMLS CUI [1])